文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

PET引导下挽救性淋巴结放疗联合临时雄激素剥夺治疗N1和M1a激素敏感性前列腺癌的十年结局

Ten-Year Outcomes of Positron Emission Tomography-Directed Salvage Nodal Radiation Therapy and Temporary Androgen Deprivation Therapy for N1 and M1a Hormone-Sensitive Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2026-09-15

该回顾性队列纳入93例根治性治疗后PET检出淋巴结复发、无远处转移的激素敏感性前列腺癌患者,接受PET引导的选择性淋巴结放疗(ENRT)联合同步整合推量(SIB)及中位2年雄激素剥夺治疗(ADT)。中位随访10.0年,5/10年总生存率为95%/77%,前列腺癌特异性生存率为96%/87%,3级泌尿/胃肠毒性发生率低,但远处转移无进展生存率10年降至31%。

要点

  • PET引导ENRT+SIB联合临时ADT后10年OS 77%、PCSS 87%,3级GU/GI毒性仅4.3%/1.1%。
  • 仅盆腔淋巴结复发者10年OS和PCSS显著优于髂总/腹主动脉旁受累者(93% vs 70%,96% vs 83%)。
  • 10年BRFS 38%、DMFS 31%,提示远处转移风险仍高。

核心结论

  • 在该回顾性队列的选定患者中,PET引导ENRT联合SIB及以临时ADT为主的方案,长期生存良好且3级毒性发生率低。

研究设计与样本

  • 回顾性队列研究,纳入93例根治性治疗后PET检出仅淋巴结复发、无远处转移的激素敏感性前列腺癌患者。
  • 患者接受ENRT(选择性照射45-50 Gy,SIB 50-62.5 Gy)联合ADT(中位2年)。

主要发现

  • 中位随访10.0年,5/10年OS为95%/77%,PCSS为96%/87%。
  • 盆腔仅复发者对比髂总/腹主动脉旁受累者,10年OS为93% vs 70%(P = .01),PCSS为96% vs 83%(P = .04)。
  • 5/10年BRFS为46%/38%,DMFS为54%/31%,去势抵抗性前列腺癌无进展生存率为79%/55%,无治疗生存率为55%/35%。
  • 无归因于ENRT的急性3级事件,10年3级泌尿/胃肠毒性发生率为4.3%/1.1%;5年正常睾酮恢复(>240 ng/dL)率为51.7%。
  • Cox模型C指数BRFS为0.69、DMFS为0.79。

关键数值与推荐

  • 复发时中位PSA为2.7 ng/mL,中位PET阳性淋巴结数为2个。
  • 30%患者为盆腔仅复发,70%患者为髂总和/或腹主动脉旁受累。

临床怎么用

  • 该成熟结局可为选定患者的咨询提供长期基准。
  • 需前瞻性评估以确立该联合模式在已演变治疗范式下的长期获益。

局限性

  • 回顾性队列设计,样本量有限(93例),存在选择偏倚可能。
  • 需前瞻性研究验证长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate long-term outcomes of positron emission tomography (PET)-directed elective nodal radiation therapy (ENRT) with simultaneous integrated boost (SIB) plus fixed-duration androgen deprivation therapy (ADT) for pelvic and/or paraaortic oligorecurrent hormone-sensitive prostate cancer. METHODS AND MATERIALS: Patients with hormone-sensitive prostate cancer with PET-detected nodal-only recurrence after curative-intent primary therapy were treated with ENRT (45-50 Gy elective, SIB 50-62.5 Gy), plus ADT (median, 2 years). Outcomes included overall survival (OS), prostate cancer-specific survival (PCSS), biochemical relapse-free survival (BRFS), distant metastasis-free survival (DMFS), castration-resistant prostate cancer-free survival, treatment-free survival, and National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 toxicity. Multivariable Cox regression explored factors associated with BRFS and DMFS. RESULTS: Ninety-three patients had a median follow-up of 10.0 years. Median prostate-specific antigen at recurrence was 2.7 ng/mL, with 2 PET-positive nodes; 30% had pelvic-only and 70% had common iliac and/or paraaortic involvement. OS at 5/10 years was 95%/77%, and PCSS was 96%/87%. Patients with pelvic-only versus common iliac/paraaortic disease had higher 10-year OS (93% vs 70%; P = .01) and PCSS (96% vs 83%; P = .04). At 5/10 years, BRFS was 46%/38%, DMFS was 54%/31%, castration-resistant prostate cancer-free survival was 79%/55%, and treatment-free survival was 55%/35%. No acute G3 events attributable to ENRT occurred; 10-year G3 genitourinary/gastrointestinal rates were 4.3%/1.1%. Normal testosterone recovery (>240 ng/dL) reached 51.7% at 5 years. Cox models had C-indices of 0.69 for BRFS and 0.79 for DMFS. CONCLUSIONS: Among selected patients in this retrospective cohort, PET-directed ENRT with SIB and predominantly temporary ADT was followed by favorable long-term survival and low observed rates of grade 3 toxicity. These mature outcomes provide long-term benchmarks for patient counseling, although prospective evaluation is needed to establish the long-term benefit of this combined-modality approach in the context of treatment paradigms that have since evolved.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Salazar CJ, Wilhite TJ, Stish BJ, et al. Ten-Year Outcomes of Positron Emission Tomography-Directed Salvage Nodal Radiation Therapy and Temporary Androgen Deprivation Therapy for N1 and M1a Hormone-Sensitive Prostate Cancer. Pract Radiat Oncol. 2026. PMID: 42744091. doi:10.1016/j.prro.2026.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。